What the research found

Researchers identified FAD (flavin adenine dinucleotide) as a natural metabolite that dampens activation of two key viral sensors in your cells: cGAS and RIG-I. These proteins normally trigger interferon responses when they detect foreign or misplaced nucleic acids—a critical first line of immune defense.

The team screened a library of endogenous metabolites and found FAD specifically inhibited interferon signaling in a dose-dependent manner when these sensors were activated. Further work showed FAD binds directly to the catalytic sites of both cGAS and RIG-I, physically blocking their function rather than affecting downstream signaling. The inhibition appears mechanistically specific: FAD blocks cGAMP production in cGAS and ATP hydrolysis in RIG-I.

Why it matters for you

This work hints at a metabolic "brake" on antiviral immunity that your body naturally employs. If FAD levels influence how vigorously these sensors respond, this could theoretically explain why some people mount stronger or weaker interferon responses to infection or inflammatory triggers. For MyKine users tracking recovery metrics, sleep quality, or fatigue after training stress—all influenced by interferon tone—FAD status might eventually become relevant to understand.

The finding also raises a question about metabolic optimization: FAD is a central cofactor in mitochondrial function and energy metabolism. Whether you could modulate your own cGAS/RIG-I sensitivity through lifestyle, supplementation, or NAD+ precursor intake remains entirely speculative at this stage, but the connection between energy metabolism and immune checkpoint control is worth watching as the field develops.

Caveats

• In vitro screening: Initial discovery was in cultured cells, not living organisms
• Mechanism shown in reductionist systems: Binding and inhibition demonstrated; unclear how FAD levels in vivo actually constrain these sensors during real infection or inflammation
• No human data: No evidence this pathway operates the same way in people or that FAD is a limiting factor in natural conditions
• Early-stage: Long way from therapeutic or optimization application